Literature DB >> 19382221

Association of lower airway inflammation with physiologic findings in young children with cystic fibrosis.

Stacey L Peterson-Carmichael1, William T Harris, Ruchika Goel, Terry L Noah, Robin Johnson, Margaret W Leigh, Stephanie D Davis.   

Abstract

BACKGROUND: The relationship between lower airway markers of inflammation and infection with physiologic findings is poorly understood in young children with cystic fibrosis (CF). The goal of this study was to evaluate the association of bronchoalveolar lavage fluid (BALF) markers of infection and inflammation, including mediators linked to airway remodeling, to infant lung function values in young children with CF undergoing clinically indicated bronchoscopy.
METHODS: Plethysmography and the raised volume rapid thoracoabdominal compression (RVRTC) technique were performed in 16 sedated infants and young children with CF prior to bronchoscopy. BALF was collected and analyzed for pathogen density, cell count, % neutrophils, transforming growth factor beta 1 (TGF-beta(1)), matrix metalloproteinases (MMP), and interleukin-8 (IL-8).
RESULTS: There was a significant direct correlation between functional residual capacity (FRC), the ratio of residual volume to total lung capacity (RV/TLC) and FRC/TLC with % neutrophils (P < 0.05). Forced expiratory flows were inversely correlated to % neutrophils (P < 0.01). Lung function parameters did not differentiate those with and without lower airway infection; however, pathogen density directly correlated with FRC and inversely correlated with flows (P < 0.05). In a subset of the population, MMP-2 directly correlated with RV/TLC and inversely correlated with flows (P < 0.05) and TGF-beta(1) directly correlated with FRC (P < 0.05).
CONCLUSIONS: Results from this study suggest that lower airway inflammation as well as mediators linked to airway remodeling play an active role in pulmonary deterioration in CF infants and young children undergoing clinically indicated bronchoscopy. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19382221     DOI: 10.1002/ppul.21044

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  23 in total

1.  Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints.

Authors:  Stephanie D Davis; Margaret Rosenfeld; Gwendolyn S Kerby; Lyndia Brumback; Margaret H Kloster; James D Acton; Andrew A Colin; Carol K Conrad; Meeghan A Hart; Peter W Hiatt; Peter J Mogayzel; Robin C Johnson; Stephanie L Wilcox; Robert G Castile
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

2.  Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungs.

Authors:  Nicholas W Keiser; Susan E Birket; Idil A Evans; Scott R Tyler; Adrianne K Crooke; Xingshen Sun; Weihong Zhou; Joseph R Nellis; Elizabeth K Stroebele; Kengyeh K Chu; Guillermo J Tearney; Mark J Stevens; J Kirk Harris; Steven M Rowe; John F Engelhardt
Journal:  Am J Respir Cell Mol Biol       Date:  2015-06       Impact factor: 6.914

3.  TGF-β1 Suppresses the Type I IFN Response and Induces Mitochondrial Dysfunction in Alveolar Macrophages.

Authors:  Jocelyn R Grunwell; Samantha M Yeligar; Susan Stephenson; Xiao Du Ping; Theresa W Gauthier; Anne M Fitzpatrick; Lou Ann S Brown
Journal:  J Immunol       Date:  2018-02-02       Impact factor: 5.422

Review 4.  The role of matrix metalloproteinases in cystic fibrosis lung disease.

Authors:  A Gaggar; A Hector; P E Bratcher; M A Mall; M Griese; D Hartl
Journal:  Eur Respir J       Date:  2011-01-13       Impact factor: 16.671

5.  Exhaled breath condensate purines correlate with lung function in infants and preschoolers.

Authors:  Kavita Patel; Stephanie D Davis; Robin Johnson; Charles R Esther
Journal:  Pediatr Pulmonol       Date:  2012-05-21

6.  Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety.

Authors:  Margaret Rosenfeld; Stephanie Davis; Lyndia Brumback; Stephen Daniel; Ron Rowbotham; Robin Johnson; Sharon McNamara; Renee Jensen; Carol Barlow; Felix Ratjen
Journal:  Pediatr Pulmonol       Date:  2011-03-01

7.  Nasal versus oronasal raised volume forced expirations in infants--a real physiologic challenge.

Authors:  Mohy G Morris
Journal:  Pediatr Pulmonol       Date:  2012-02-10

8.  Antiproteases as therapeutics to target inflammation in cystic fibrosis.

Authors:  Derek J Quinn; Sinéad Weldon; Clifford C Taggart
Journal:  Open Respir Med J       Date:  2010-03-30

Review 9.  Novel end points for clinical trials in young children with cystic fibrosis.

Authors:  Shannon J Simpson; Lauren S Mott; Charles R Esther; Stephen M Stick; Graham L Hall
Journal:  Expert Rev Respir Med       Date:  2013-06       Impact factor: 3.772

10.  Association of lung function, chest radiographs and clinical features in infants with cystic fibrosis.

Authors:  Margaret Rosenfeld; Philip M Farrell; Margaret Kloster; Jonathan O Swanson; Thuy Vu; Lyndia Brumback; James D Acton; Robert G Castile; Andrew A Colin; Carol K Conrad; Meeghan A Hart; Gwendolyn S Kerby; Peter W Hiatt; Peter J Mogayzel; Robin C Johnson; Stephanie D Davis
Journal:  Eur Respir J       Date:  2013-05-30       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.